Alpha-Mannosidosis Market Insight, Epidemiology, And Market Forecast - 2036 Now Available. Reveals Why A Near-Absent Pipeline Leaves An Ultra-Rare Disease Reliant On A Single Approved Therapy
Dublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- The "c6" has been added to ResearchAndMarkets.com's offering.
Alpha-Mannosidosis Market Forecast to 2036 Highlights Growth Opportunities Across the 7MM
The alpha-mannosidosis market is projected to record moderate-to-steady growth between 2026 and 2036, supported by improved disease recognition, broader genetic testing, the gradual expansion of newborn screening programs, and increasing adoption of velmanase alfa-tycv (LAMZEDE). Continued research in lysosomal storage disorders and demand for therapies capable of addressing neurological manifestations are also expected to influence future market dynamics.
The "Alpha-Mannosidosis - Market Insights, Epidemiology, and Market Forecast - 2036" report provides a comprehensive assessment of the alpha-mannosidosis treatment landscape, epidemiology, market size, therapy uptake, competitive environment, and commercial opportunities across the seven major markets. Geographic coverage includes the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Alpha-Mannosidosis Market Insights and Trends
- Growth in diagnosed alpha-mannosidosis cases is primarily associated with stronger clinical awareness, wider availability of molecular testing for pathogenic MAN2B1 variants, and improved recognition of rare lysosomal storage disorders. LAMZEDE, developed by Chiesi Global Rare Diseases, remains the first and only approved enzyme replacement therapy for non-central nervous system manifestations of alpha-mannosidosis in pediatric and adult patients. The alpha-mannosidosis drug pipeline remains limited, with only a small number of early-stage or preclinical programs under evaluation. Substantial unmet medical needs persist because current therapies are not curative, require long-term administration, and have limited effects on neurological disease progression. Future opportunities include gene therapy, central nervous system-targeted treatments, and potentially curative approaches addressing both systemic and neurological manifestations.
Disease and Diagnostic Landscape
Alpha-mannosidosis is an inherited lysosomal storage disorder associated with pathogenic variants in the MAN2B1 gene and deficient alpha-D-mannosidase activity. Clinical manifestations may include immune deficiency, recurrent infections, hearing loss, skeletal abnormalities, cognitive and speech impairment, psychiatric symptoms, muscle weakness, joint disease, and ataxia.
Diagnosis typically involves clinical assessment, oligosaccharide analysis, measurement of acid alpha-mannosidase activity in leukocytes, and molecular confirmation through MAN2B1 genetic testing. Molecular testing can also support carrier detection, prenatal diagnosis, and preimplantation genetic testing in families with confirmed pathogenic variants. The expansion of genetic and newborn screening programs may enable earlier diagnosis and intervention before irreversible organ damage occurs.
Current Alpha-Mannosidosis Treatment Landscape
Velmanase alfa-tycv is the cornerstone of the current disease-modifying treatment landscape. Administered by intravenous infusion, the recombinant human alpha-mannosidase therapy is indicated for non-central nervous system manifestations of alpha-mannosidosis. The US Food and Drug Administration approved LAMZEDE in February 2023 for adult and pediatric patients, while the European Commission granted marketing authorization in April 2018 for non-neurological manifestations in patients with mild to moderate disease.
Although LAMZEDE has demonstrated favorable tolerability and improvements in biochemical markers and selected functional outcomes, its clinical effect is constrained by limited central nervous system penetration. Hematopoietic stem cell transplantation has been evaluated in selected patients and may offer benefits when performed early, but procedural risks and variable outcomes prevent its routine use as a standard treatment.
Supportive management remains multidisciplinary and may address hearing impairment, recurrent infections, respiratory and cardiac complications, skeletal abnormalities, neurodevelopmental impairment, nutritional needs, and rehabilitation. Genetic counseling is also an important component of disease management.
Alpha-Mannosidosis Epidemiology Forecast
The report evaluates historical and forecasted alpha-mannosidosis epidemiology from 2022 to 2036 across the 7MM. It examines diagnosed patient populations, regional trends, underlying assumptions, and expert perspectives influencing projected disease burden.
- Secondary research estimates the prevalence of alpha-mannosidosis in the United States at approximately one case per 500,000 people. The disorder affects males and females in similar numbers and has been reported across ethnic groups worldwide. Published estimates for Italy range from approximately one case per 250,000 to one per million live births, reflecting the ultra-rare status of the condition.
The report distinguishes between changes in underlying prevalence and increases in diagnosed cases. Improved awareness, expanded genetic testing, and better referral pathways are expected to increase identification rates, particularly among patients who may previously have remained undiagnosed.
Alpha-Mannosidosis Market Size, Drug Uptake, and Access
The analysis assesses alpha-mannosidosis market size, revenue, therapy share, peak patient share, treatment uptake, and growth projections by country and therapy. In 2025, the United States represented a significant share of the 7MM market, supported by diagnosed prevalence, treatment costs, and access to approved therapy. The US is expected to retain a leading position during the forecast period, although reimbursement decisions and the timing of future product launches may affect regional performance.
The drug uptake analysis evaluates the anticipated market penetration of recently launched and potential future alpha-mannosidosis therapies between 2022 and 2036. It also considers regulatory milestones, financial factors, class-level competition, and probability of commercial success.
Country-specific market access analysis covers healthcare systems, reimbursement policies, health technology assessments, treatment availability, accessibility barriers, and patient support programs. These factors remain critical in an ultra-rare market characterized by high treatment costs and uneven access across regions.
Competitive Intelligence and Strategic Value
The alpha-mannosidosis market report combines primary and secondary research to assess current treatment practices, emerging therapeutic approaches, competitive positioning, and unmet needs. Insights from key opinion leaders and subject-matter experts help validate market trends, treatment patterns, therapy acceptance, patient compliance challenges, and expectations for future innovation.
Competitive intelligence includes SWOT analysis, market-entry considerations, cross-country comparisons, and evaluation of potential commercial opportunities. The report is designed to support pharmaceutical companies, biotechnology developers, investors, healthcare organizations, and other rare disease stakeholders with evidence-based strategic planning.
Key Report Benefits
- Eleven-year alpha-mannosidosis market and epidemiology forecasts through 2036. Coverage of the United States, EU4, the United Kingdom, and Japan. Country-level analysis of diagnosed patient populations and treatment trends. Assessment of LAMZEDE uptake, market share, regulatory milestones, and commercial performance. Evaluation of treatment practices, reimbursement conditions, and access barriers. Analysis of unmet needs and opportunities for CNS-penetrating, gene-based, and potentially curative therapies. Competitive intelligence supporting market-entry, development, and launch strategies.
The alpha-mannosidosis market outlook remains closely tied to earlier diagnosis, sustained use of LAMZEDE, regional reimbursement conditions, and future therapeutic innovation. With neurological progression remaining a major treatment limitation, therapies capable of reaching the central nervous system and addressing the full multisystem burden of alpha-mannosidosis may create significant clinical and commercial value through 2036.
A selection of companies mentioned in this report includes, but is not limited to:
- Chiesi Farmaceutici S.p.A
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment